Primary localized amyloidosis
MONDO:0017817Primary localized amyloidosis is a form of AL amyloidosis caused by the aggregation of insoluble amyloid fibrils derived from misfolded monoclonal immunoglobulin light chains usually produced by a plasma cell tumor and characterized by localized amyloid deposition with clinical manifestations restricted to the organ involved, most frequently urinary tract (bladder), eye, respiratory tract (larynx, lungs), and skin.
Also known as: localised AL amyloidosis, localized AL amyloidosis
11 clinical trials for this condition and its sub-types, 0 tagged with Primary localized amyloidosis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
Could a short course of steroids calm a dangerous heart rhythm?
Disease control By invitation onlyThis trial tests whether an 8-week course of the immunosuppressive drug prednisone can reduce episodes of ventricular tachycardia (a potentially fatal fast heart rhythm) and improve heart function in people with non-ischemic cardiomyopathy and confirmed heart inflammation. Partic…
Phase 4 • Sponsor: Roderick Tung • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Super MRI could spot hidden heart damage
Diagnosis OngoingThis study tests whether a new, more powerful 7 Tesla MRI can better detect scarring and swelling in the heart muscle of people with cardiomyopathy. Researchers will scan 13 adults aged 20-70 to see if the higher-resolution images improve diagnosis. The goal is to see if this adv…
Sponsor: University of Pennsylvania • Aim: Diagnosis
Last updated Jun 27, 2026 09:02 UTC
-
Can a gene registry unlock the secrets of childhood heart failure?
Knowledge-focused OngoingThis study gathers health information from children under 18 who have cardiomyopathy linked to mutations in the MYBPC3 gene. Researchers aim to map the disease's natural course, identify risk factors, and measure how it affects quality of life. By reviewing past and future medica…
Sponsor: Tenaya Therapeutics • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC